At a glance
ClinicalIndex Comparison RecordPhase 4Unknown· 290 target
Drug / intervention
Rituximab +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Four Cycles of R-CHOP Followed by Four Cycles of Rituximab Versus Six Cycles of R-CHOP Followed by Two Cycles of Rituximab in the Treatment of de Novo, Low-risk, Non-bulky Diffuse Large B-cell Lymphoma.
In Brief
A Phase 4 clinical trial evaluating Rituximab, Cyclophosphamide, and 3 other interventions for Diffuse Large B-cell Lymphoma. Targeting 290 participants across 1 site.
Detailed Summary
This is a clinical trial to compare the efficacy and safety of four cycles of R-CHOP followed by four cycles of Rituximab with six cycles of R-CHOP followed by two cycles of Rituximab in the treatment of de novo, low-risk, non-bulky diffuse large B-cell lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large B-cell Lymphoma
CountriesChina
Collaborators--
Timeline
Phase 4UnknownOverdue
2017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartJun 2016
Primary CompletionOct 2022
Study CompletionDec 2024
TodayJul 2026
First PostedApr 27, 2016
Enrollment StartJun 14, 2016
Primary CompletionOct 30, 2022
Study CompletionDec 31, 2024
TodayJul 1, 2026
Enrollment to primary: 6.4 yearsPosted 10.2 years ago
Interventions
Rituximabdrug
Cyclophosphamidedrug
Epirubicindrug
Vincristinedrug
Prednisonedrug